List view / Grid view
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals...
19 June 2014 | By H. Lundbeck A/S
Lundbeck will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs. escitalopram in patients with well treated Major Depressive Disorder...
18 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablet...
18 June 2014 | By Novartis
For its first "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals...
18 June 2014 | By Bristol-Myers Squibb
The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-six cents per share on the $.10 par value Common Stock of the corporation...
17 June 2014 | By GEA Group
GEA Process Engineering’s Pharmaceutical GMP Spray Drying facility in Copenhagen, Denmark has been granted authorization by the Danish Health and Medicines Authority for spray drying of human medicinal products for commercial use...
17 June 2014 | By kdm communications
Tecan has introduced a Dual Z arm for the popular Cavro® Omni Robot...
17 June 2014 | By Novartis
Novartis announced the submission of a Biologic License Application to the US Food and Drug Administration for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine...
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
17 June 2014 | By AbbVie
AbbVie announced that the Marketing Authorization Applications for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus infection have been validated and are under accelerated assessment by the European Medicines Agency...
16 June 2014 | By Pfizer
Pfizer Inc. announced the opening of a new 280,000 square-foot Research and Development hub in Cambridge, Mass...
16 June 2014 | By Novo Nordisk
Data from a new phase 3 study demonstrated that once-daily Victoza® (liraglutide) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment...
16 June 2014 | By Novartis
Novartis announced that the US Food and Drug Administration licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines...
16 June 2014 | By GlaxoSmithKline
New data from secondary analyses of four randomised phase III studies being presented at the 74th Scientific Sessions of the American Diabetes Association...
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
